fluocinolone (Iluvien, Alimera Sciences)

Opinion: Time to Manage ‘Clinically Superfluous’ Drug Products to Control CostsPBMs are in a unique position to leverage three critical tools to protect patients from unnecessary healthcare costs.
Intravitreal implant could bring significant cost savings to NHS EnglandA study has revealed that a budgetary saving per treated patient with the fluocinolone acetonide implant (Iluvien) versus ranibizumab (Lucentis) could lead to a significant cost-saving to NHS England.
Data demonstrate real-world benefits of fluocinolone acetonide implantReal-world data on a fluocinolone acetonide intravitreal implant show sustained benefits of switching to the treatment in pseudophakic eyes that are insufficiently responsive to other therapies.
Study: Fluocinolone acetonide 0.2 µg/day reduced DR progressionTreatment with fluocinolone acetonide 0.2 µg/day significantly reduced progression to proliferative diabetic retinopathy (PDR) in patients who were part of the FAME trials1,2 and had visual acuity loss due to diabetic macular edema (DME), according to Charles C. Wykoff, MD, PhD.
Real-world experience provides clarity to intravitreal injection misconceptionUsing real-world experience, a retinal surgeon highlights the optimal settings for use of steroid implants for treatment of diabetic macular edema.